Healthcare / BiotechnologyShanghai
$17.57
-0.25 (-1.40%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $205.2M · quality 44.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.9B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-7.9%
↓Gross Margin
50.2%
↑Debt/Equity
0.18
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-18.6%
FCF CAGR
—
FCF margin
8.4%
FCF / Net income
-0.78x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.45B · net income $-262.4M · FCF $205.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.45B | $2.45B | $3.78B | $4.20B | $4.54B |
| Net Income | $-262.4M | $-262.4M | $123.7M | $184.8M | $335.2M |
| EBITDA | $-7.2M | $-7.2M | $382.7M | $414.9M | $518.7M |
| EPS | -0.59 | -0.59 | 0.28 | 0.41 | 0.74 |
| Gross Margin | 50.2% | 50.2% | 57.8% | 62.7% | 64.6% |
| Operating Margin | -7.9% | -7.9% | 6.8% | 6.4% | 8.7% |
| Net Margin | -10.7% | -10.7% | 3.3% | 4.4% | 7.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.18 | 0.18 | 0.20 | 0.13 | 0.07 |
| Current Ratio | 1.97 | 1.97 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $205.2M | $205.2M | $79.6M | $288.0M | $-669.1M |
| Returns | |||||
| ROE | -7.9% | -7.9% | 3.5% | 5.2% | 8.4% |
| Valuation | |||||
| P/E | — | — | 51.32 | 48.15 | 28.54 |
| EV/EBITDA | — | — | 14.95 | 18.99 | 15.78 |
| P/B | 2.36 | 2.36 | 1.77 | 2.48 | 2.40 |
| Growth & Yield | |||||
| Revenue Growth | -35.3% | -35.3% | -9.9% | -7.6% | — |
| EPS Growth | -310.7% | -310.7% | -31.7% | -44.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+21.3%
Start / end P/E
n/dx → n/dx
EPS bridge
0.28 → -0.59
Residual
+21.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.